Quality assurance for the EORTC 22071–26071 study: dummy run prospective analysis

Radiation Oncology

Wilfried Budach³  Damien C Weber⁹  Sunita Ghosh²  Akos Gulyban⁵  Danny Schuring⁶  Milan Tomsej⁹  Christopher Scrase⁷  Sandra Nuyts⁴  Johannes A Langendijk¹  Alysa Fairchild⁸ 

[1] Department of Radiation Oncology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands;Department of Experimental Oncology, Cross Cancer Institute, Edmonton, Canada;Department of Radiation Oncology, Heinrich Heine University, Dusseldorf, Germany;Department of Radiation Oncology, University Hospital Leuven, KU Leuven, Leuven, Belgium;Department of Radiation Oncology, University Hospital of Liege, Liege, Belgium;Department of Radiotherapy, Catharina Hospital, Eindhoven, The Netherlands;Department of Radiation Oncology, Ipswich Hospital, Ipswich, UK;Department of Radiation Oncology, Cross Cancer Institute, 11560 University Avenue, Edmonton, T6G 1Z2, AB, Canada;EORTC Quality Assurance in Radiotherapy Team, Brussels, Belgium

关键词: EORTC ROG;    Dummy run;    IMRT;    Head and neck;   

Others  :  1228542
DOI  :  10.1186/s13014-014-0248-9

 received in 2014-01-18, accepted in 2014-11-04,  发布年份 2014

【 摘 要 】

Purpose

The phase III 22071–26071 trial was designed to evaluate the addition of panitumumab to adjuvant chemotherapy plus intensity modulated radiotherapy (IMRT) in locally advanced resected squamous cell head and neck cancer. We report the results of the dummy run (DR) performed to detect deviations from protocol guidelines.

Methods and Materials

DR datasets consisting of target volumes, organs at risk (OAR) and treatment plans were digitally uploaded, then compared with reference contours and protocol guidelines by six central reviewers. Summary statistics and analyses of potential correlations between delineations and plan characteristics were performed.

Results

Of 23 datasets, 20 (87.0%) GTVs were evaluated as acceptable/borderline, along with 13 (56.5%) CTVs and 10 (43.5%) PTVs. All PTV dose requirements were met by 73.9% of cases. Dose constraints were met for 65.2-100% of mandatory OARs. Statistically significant correlations were observed between the subjective acceptability of contours and the ability to meet dose constraints for all OARs (p ≤ 0.01) except for the parotids and spinal cord. Ipsilateral parotid doses correlated significantly with CTV and PTV volumes (p ≤ 0.05).

Conclusions

The observed wide variations in treatment planning, despite strict guidelines, confirms the complexity of development and quality assurance of IMRT-based multicentre studies for head and neck cancer.

【 授权许可】

   
2014 Fairchild et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Huang DT, Johnson CR, Schmidt-Ullrich R, Grimes M: Postoperative radiotherapy in head and neck carcinoma with extracapsular lymph node extension and/or positive resection margins: a comparative study. Int J Radiat Oncol Biol Phys 1992, 23(4):737-742.
• [2]Kokal WA, Neifeld JP, Eisert D, Lipsett JA, Lawrence W Jr, Beatty JD, Parker GA, Pezner RD, Riihimaki DU, Terz JJ: Postoperative radiation as adjuvant treatment for carcinoma of the oral cavity, larynx, and pharynx: preliminary report of a prospective randomized trial. J Surg Oncol 1988, 38(2):71-76.
• [3]Marcial VA, Pajak TF, Kramer S, Davis LW, Stetz J, Laramore GE, Jacobs JR, Al-Sarraf M, Brady LW: Radiation therapy oncology group studies in head and neck cancer. Semin Oncol 1988, 15(1):39-60.
• [4]Sadeghi A, McLaren J, Grist WL, Tran L, Kuisk H: Value of radiation therapy in addition to surgery for cancer of the head and neck. Otolaryngol Head Neck Surg 1986, 94(5):601-604.
• [5]Fietkau R, Lautenschläger C, Sauer R, Dunst J, Becker A, Baumann M, Wendt K, Gruschow K, Hess C, Budach V, Iro H: Postoperative concurrent radiochemotherapy versus radiotherapy in high-risk SCCA of the head and neck: results of the german phase III trial ARO 96–3 [abstract]. J Clin Oncol 2006, 24(June 20 Suppl 18S):5507.
• [6]Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefebvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M: European Organization for Research and Treatment of Cancer Trial 22931: European organization for research and treatment of cancer trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004, 350(19):1945-1952.
• [7]Cooper JS, Pajak TF, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lefebvre JL: Radiation therapy oncology group 9501/intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004, 350(19):1937-1944.
• [8]Peters LJ, Goepfert H, Ang KK, Byers RM, Maor MH, Guillamondegui O, Morrison WH, Weber RS, Garden AS, Frankenthaler RA: Evaluation of the dose for postoperative radiation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys 1993, 26(1):3-11.
• [9]Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lefebvre JL: Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck 2005, 27(10):843-850.
• [10]Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354(6):567-578.
• [11]Fairchild A, Straube W, Laurie F, Followill D: Does quality of radiotherapy predict outcomes of multicentre cooperative group trials? A literature review. Int J Radiat Oncol Biol Phys 2013, 87(2):246-260.
• [12]Ohri N, Shen X, Dicker A, Doyle L, Harrison A, Showalter T: Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials. J Natl Cancer Inst 2013, 105(6):387-393.
• [13]Weber D, Tomsej M, Melidis C, Hurkmans C: QA makes a clinical trial stronger: evidence-based medicine in radiation therapy. Radiother Oncol 2012, 105(1):4-8.
• [14]Abrams RA, Winter KA, Regine WF, Safran H, Hoffman JP, Lustig R, Konski AA, Benson AB, Macdonald JS, Rich TA, Willett CG: Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704–a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 2012, 82(2):809-816.
• [15]Peters LJ, O’Sullivan B, Giralt J, Fitzgerald TJ, Trotti A, Bernier J, Bourhis J, Yuen K, Fisher R, Rischin D: Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02. J Clin Oncol 2012, 28(18):2996-3001.
• [16]Weber D, Poortmans P, Hurkmans C, Aird E, Gulyban A, Fairchild A: Quality assurance for prospective EORTC radiation oncology trials: the challenges of advanced technology in a multicentre international setting. Radiother Oncol 2011, 100(1):150-156.
• [17]Ibbott G, Followill D, Molineu H, Lowenstein J, Alvarez P, Roll J: Challenges in credentialing institutions and participants in advanced technology multi-institutional clinical trials. Int J Radiat Oncol Biol Phys 2008, 71(1 Suppl):S71-S75.
• [18]Williams M, Bailey M, Forstner D, Metcalfe P: Multicentre quality assurance of intensity-modulated radiation therapy plans: a precursor to clinical trials. Australas Radiol 2007, 51:472-479.
• [19]Fairchild A, Collette L, Hurkmans C, Baumert B, Weber DC, Gulyban A, Poortmans P: Do results of the EORTC dummy run predict quality of radiotherapy delivered within multicentre clinical trials? Eur J Cancer 2012, 48:3232-3239.
• [20]Ang K, Zhang Q, Rosenthal D, Nguyen-Tan PF, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar AK, Gillison ML, Jordan RC, Konski AA, Thorstad WL, Trotti A, Beitler JJ, Garden AS, Spanos WJ, Yom SS, Axelrod RS: A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas [Abstract]. J Clin Oncol 2011, 29(Suppl):5500.
• [21]Gregoire V, Eisbruch A, Hamoir M, Levendag P: Proposal for the delineation of the nodal CTV in the node-positive and post-operative neck. Radiother Oncol 2006, 79(1):15-20.
• [22]ICRU Report 83: Prescribing, recording and reporting photon beam intensity-modulated radiotherapy J ICRU 2010, 10(1):1-106.
• [23]Das I, Cheng C, Chopra K, Mitra R, Srivastava S, Glatstein E: Intensity-modulated radiation therapy dose prescription, recording and delivery: Patterns of variability among institutions and treatment planning systems. J Natl Cancer Inst 2008, 100(5):300-307.
• [24]Clark C, Miles A, Guerrero Urbano M, Bhide SA, Bidmead AM, Harrington KJ, Nutting CM: Pre-trial quality assurance processes for an intensity-modulated radiation therapy trial: PARSPORT, a UK multicentre phase III trial comparing conventional radiotherapy and parotid-sparing IMRT for locally advanced head and neck cancer. Brit J Radiol 2009, 82:585-594.
• [25]Moeckli R, Sozzi W, Mirimanoff R, Ozsahin M, Zouhair A, Valley JF, Bochud F: Physical considerations on discrepancies in target volume delineation. Z Med Phys 2009, 19:224-235.
• [26]Nelms B, Tome W, Robinson G, Wheeler J: Variations in the contouring of organs at risk: test case from a patient with oropharyngeal cancer. Int J Radiat Oncol Biol Phys 2012, 82(1):368-378.
• [27]Chao K, Low D, Perez C, Purdy J: Intensity-modulated radiation therapy in head and neck cancers: the mallinkrodt experience. Int J Cancer 2000, 90:92-103.
• [28]Skala M, Holloway L, Bailey M, Kneebone A: Australia-wide comparison of intensity modulated radiation therapy prostate plans. Australas Radiol 2005, 49:222-229.
• [29]Fairchild A, Bar-Deroma R, Collette L, Haustermans K, Hurkmans C, Lacombe D, Maingon P, Poortmans P, Tomsej M, Weber DC, Gregoire V: Development of clinical trial protocols involving advanced radiation therapy techniques: the EORTC radiation oncology group approach. Eur J Cancer 2012, 48(7):1048-1054.
• [30]Troost E, Schinagl D, Bussink J, Oyen W, Kaanders J: Clinical evidence on PET-CT for radiation therapy planning in head and neck tumours. Radiother Oncol 2010, 96:328-334.
• [31]Koshy M, Paulino A, Howell R, Schuster D, Halkar R, Davis L: F-18 FDG PET-CT fusion in radiotherapy treatment planning for head and neck cancer. Head Neck 2005, 27:494-502.